Tumor treating fields: a new treatment for glioblastoma

References

• Stevens G, Glioblastoma In. DynaMed Plus. 18.03.2019 [Zugriff: 15.04.2019]. Available from http://www.dynamed.com/topics/dmp∼AN∼T116043/Glioblastoma.
   Google Scholar
• Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: primary brain and other Central nervous system tumors diagnosed in the United States in 2012-2016. Neuro-Oncology. 2019;21(Supplement_5):v1–v100.
   PubMedGoogle Scholar
• Weller M, Van den Bent M, Tonn JC, European Association for Neuro-Oncology (EANO) Task Force on Gliomas, et al. European association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18(6):e315–e329.
   PubMed Web of Science ®Google Scholar
• Goldbrunner R, Ruge M, Kocher M, et al. The treatment of gliomas in adulthood. Dtsch Arztebl Int. 2018;115(20-21):356–364.
   PubMed Web of Science ®Google Scholar
• Wick W. Neue behandlungsoptionen bei gliomen.New treatment options for gliomas. Onkologe. 2019;25(1):60–66.
   Google Scholar
• Wick W, et al. Gliome, S2k-Leitlinie, 2021. In: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. Available from www.dgn.org/leitlinien.
   Google Scholar
• Fabian D, Guillermo Prieto Eibl M, Alnahhas I, et al. Treatment of glioblastoma (GBM) with the addition of Tumor-Treating fields (TTF): A review. Cancers. 2019;11(2):174.
   PubMed Web of Science ®Google Scholar
• Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306–2316.
   PubMed Web of Science ®Google Scholar
• Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Ann N Y Acad Sci. 2013;1291:86–95.
   PubMed Web of Science ®Google Scholar
• Wenger C, Salvador R, Basser PJ, et al. Improving tumor treating fields treatment efficacy in patients with glioblastoma using personalized array layouts. Int J Radiat Oncol Biol Phys. 2016;94(5):1137–1143.
   PubMed Web of Science ®Google Scholar
• Regev O, Merkin V, Blumenthal DT, et al. Tumor-Treating fields for the treatment of glioblastoma: a systematic review and meta-analysis. Neurooncol Pract. 2021;8(4):426–440.
   PubMed Web of Science ®Google Scholar
• Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2192–2202.
   PubMed Web of Science ®Google Scholar
• FDA Approves Expanded Indication for Medical Device to Treat Glioblastoma Multiforme | ESMO. Available online: https://www.esmo.org/Oncology-News/FDA-Approves-Expanded-Indication-for-Medical-Device-to-Treat-Glioblastoma-Multiforme.
   Google Scholar
• Ram Z, Kim CY, Hottinger AF, et al. Efficacy and safety of tumor treating fields (TTFields) in elderly patients with newly diagnosed glioblastoma: Subgroup analysis of the phase 3 EF-14. Front Oncol. 2021;11:671972.
   PubMed Web of Science ®Google Scholar
• Bokstein F, Blumenthal D, Limon D, et al. Concurrent tumor treating fields (TTFields) and radiation therapy for newly diagnosed glioblastoma: a prospective safety and feasibility study. Front Oncol. 2020;10:411.
   PubMed Web of Science ®Google Scholar
• Lu G, Rao M, Zhu P, et al. Triple-drug therapy with bevacizumab, irinotecan, and temozolomide plus tumor treating fields for recurrent glioblastoma: a retrospective study. Front Neurol. 2019;10:42.
   PubMed Web of Science ®Google Scholar
• Lazaridis L, Schäfer N, Teuber-Hanselmann S, et al. Tumour treating fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma. J Cancer Res Clin Oncol. 2020;146(3):787–792.
   PubMed Web of Science ®Google Scholar
• Song A, Bar-Ad V, Martinez N, et al. Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma. J Neurooncol. 2020;147(3):653–661.
   PubMed Web of Science ®Google Scholar
• Olubajo F, Thorpe A, Davis C, et al. Tumour treating fields in glioblastoma: is the treatment tolerable, effective, and practical in UK patients? Br J Neurosurg. 2022;24:1–7.
   Google Scholar
• Cappelli L, Kanyne A, PAn PC, et al. Chemoradiation treatment with or without concurrent Tumor-Treating fields (TTFields) in patients with newly diagnosed glioblastoma (GBM). Int J Radiat Oncol Biol Phys. 2022;114(3):e68.
   Web of Science ®Google Scholar
• Korshoej AR, Mikic N, Hansen FL, et al. Enhancing tumor treating fields therapy with skull-remodeling surgery. The role of finite element methods in surgery planning. Annu Int Conf IEEE Eng Med Biol Soc. 2019.2019;6995–6997.
   PubMedGoogle Scholar
• Zhu J-J, O'Donnell R, Ram Z. EF-19, a post-approval registry study of tumor treating fields (TTFields) in recurrent glioblastoma (rGBM). J Clin Oncol. 2020;38(15_suppl):e14536–e14536.
   Web of Science ®Google Scholar
• Fallah J, Chaudhary RT, Rogers LR, et al. Clinical outcomes of the combination of bevacizumab and TTFields in patients with recurrent glioblastoma: results of a phase II clinical trial. J Clin Oncol. 2020;38(15_suppl):2537–2537.
   Web of Science ®Google Scholar
• Kirson ED, Dbalý V, Tovarys F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci USA. 2007;104(24):10152–10157.
   PubMed Web of Science ®Google Scholar
• Hottinger AF, Pacheco P, Stupp R, et al. Tumor treating fields: a novel treatment modality and its use in brain tumors. Neuro Oncol. 2016;18(10):1338–1349.
   PubMed Web of Science ®Google Scholar
• Topfer LA, Farrah K. Alternating electric fields (“Tumour-Treating fields”) for the treatment of glioblastoma. CADTH Issues in Emerging Health Technologies. 2016;165. Available from https://www.ncbi.nlm.nih.gov/books/NBK513128/
   Google Scholar
• Novocure. Novocure reports fourth quarter and full year 2019 financial results and provides company update. Available from https://www.novocure.com/novocure-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-company-update/. 2020.
   Google Scholar
• Swanson KD, Lok E, Wong ET, et al. An overview of alternating electric fields therapy (NovoTTF therapy) for the treatment of malignant glioma. Curr Neurol Neurosci Rep. 2016;16(1):8.
   PubMed Web of Science ®Google Scholar
• Mrugala MM, Engelhard HH, Dinh Tran D, et al. Clinical practice experience with NovoTTF-100A™ system for glioblastoma: the patient registry dataset (PRiDe). Semin Oncol. 2014;41: s4–S13.
   PubMed Web of Science ®Google Scholar
• Gentilal N, Salvador R, Miranda PC. A thermal study of tumor-treating fields for glioblastoma therapy. In: Makarov SN, Noetscher GM, Nummenmaa A, editors. Brain and human body modeling 2020: computational human models presented at EMBC 2019 and the BRAIN initiative® 2019 meeting. Cham: Springer; 2021.
   Google Scholar
• Branter J, Basu S, Smith S, et al. Tumour treating fields in a combinational therapeutic approach. Oncotarget. 2018;9(93):36631–36644.
   PubMedGoogle Scholar
• Gera N, Yang A, Holtzman TS, et al. Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit. PLoS One. 2015;10(5):e0125269.
   PubMed Web of Science ®Google Scholar
• Estey MP, Di Ciano-Oliveira C, Froese CD, et al. Distinct roles of septins in cytokinesis: SEPT9 mediates midbody abscission. J Cell Biol. 2010;191(4):741–749.
   PubMed Web of Science ®Google Scholar